Circulating Tumor DNA in Upper Tract Urothelial Carcinoma: A Framework for Precision Perioperative Management Authors: Amulya Prakash, Adriani Cherico, Adanma Ayanambakkam, Hyma Vani Polimera Published: 2026 ABSTRACT Simple SummaryUpper tract urothelial carcinoma (UTUC) is a rare cancer of the renal pelvis and ureter that is difficult to diagnose, stage accurately, and treat, with many patients experiencing recurrence even after surgery. Current treatment decisions rely largely on clinical and pathological features that are often insufficient. Circulating tumor DNA (ctDNA) is an emerging biomarker that can detect molecular residual disease and may identify patients at higher risk of recurrence, enabling more personalized treatment. However, UTUC-specific evidence remains limited, and most available data are extrapolated from bladder cancer or broader urothelial carcinoma studies. In this narrative review, we synthesize the current evidence and propose a research framework for integrating ctDNA in UTUC perioperative management. We emphasize that ctDNA-guided treatment escalation, de-escalation, and surveillance modification remain investigational and require prospective UTUC-focused validation before routine clinical implementation. 1. Introduction Upper tract urothelial carcinoma (UTUC), involving the ureter and renal pelvis, accounts for approximately 5–10% of all urothelial cancers (UC) [1]. The management of UTUC presents unique challenges. While transurethral resection of bladder tumor (TURBT) is the diagnostic standard for UC of the bladder, ureteroscopic biopsy in UTUC is often limited by tumor location, small biopsy volume, cautery artifact, and the thin-walled anatomy of the upper tract. Ureteroscopic tumor biopsy understages UTUC in up to 46% of the cases [2]. Current risk stratification relies heavily on tumor grade, radiographic findings, hydronephrosis, multifocality, lymphovascular invasion, pathologic stage, and nodal status. These variables are clinically useful but imperfect surrogates for occult systemic disease. Current clinicopathologic models may therefore inadequately identify micrometastatic disease and unreliably predict which patients are most likely to benefit from perioperative systemic therapy. As a result, perioperative systemic therapy may overtreat some patients while failing to prevent recurrence in others. Despite curative-intent radical nephroureterectomy (RNU) for localized high-risk disease, recurrence rate remains high, particularly among patients with ≥pT2 disease, lymphovascular invasion, positive margins, or nodal involvement [3]. This clinical ambiguity necessitates the development of reliable biomarkers for prognostication and treatment stratification. Circulating tumor DNA (ctDNA) is a non-invasive biomarker that may detect molecular residual disease (MRD) after definitive local therapy. In urothelial carcinoma, ctDNA has shown prognostic value in bladder cancer and in limited UTUC-specific cohorts; however, the evidence base in UTUC remains substantially less mature. Importantly, prognostic value should be distinguished from predictive value. A prognostic biomarker identifies patients at higher risk of recurrence, whereas a predictive biomarker identifies patients more likely to benefit from a specific treatment. In UTUC, ctDNA is best viewed at present as a promising prognostic tool and investigational predictive biomarker. This narrative review synthesizes the current evidence and proposes a disease-specific research framework for evaluating ctDNA and utDNA across the perioperative UTUC continuum. The proposed framework is not intended as a clinical algorithm and should not be used to guide routine treatment escalation, de-escalation, or surveillance modification outside prospective studies. A conceptual overview of investigational ctDNA integration across the perioperative UTUC continuum is illustrated in Figure 1. 2. Methods This article is a narrative review rather than a systematic review. A structured literature search was performed to identify relevant studies evaluating ctDNA, utDNA, MRD, perioperative systemic therapy, and clinical trials in UTUC and urothelial carcinoma. PubMed/MEDLINE, ClinicalTrials.gov, and major oncology meeting abstracts were searched from January 2010 through May 2026. Search terms included combinations of: “upper tract urothelial carcinoma,” “UTUC,” “urothelial carcinoma,” “bladder cancer,” “circulating tumor DNA,” “ctDNA,” “molecular residual disease,” “MRD,” “urine tumor DNA,” “utDNA,” “perioperative,” “neoadjuvant,” “adjuvant,” “immunotherapy,” “enfortumab vedotin,” “antibody-drug conjugate,” and “surveillance.” Priority was given to prospective trials, randomized studies, UTUC-specific ctDNA studies, urothelial carcinoma studies that included UTUC patients, and high-quality translational studies relevant to MRD detection. Studies were excluded if they did not address urothelial carcinoma, did not include perioperative or MRD-relevant biomarker data, or were not available in English. Because this was not a systematic review, formal risk-of-bias assessment and meta-analysis were not performed. Evidence was categorized as UTUC-specific, bladder cancer-specific, pan-urothelial/unstratified, or hypothesis-generating extrapolation. 3. Current Treatment Landscape in Upper Tract Urothelial Cancer UTUC remains underrepresented in prospective perioperative clinical trials, and many treatment recommendations continue to be extrapolated from bladder cancer data. Radical nephroureterectomy (RNU) with complete bladder cuff excision remains the foundation of curative-intent management for high-risk disease, whereas kidney-sparing approaches are generally reserved for carefully selected low-risk tumors [4,5]. The phase III POUT trial established adjuvant platinum-based chemotherapy as an evidence-based perioperative treatment option for patients with resected high-risk UTUC. In patients with ≥pT2 or node-positive disease following RNU, adjuvant gemcitabine plus cisplatin or carboplatin significantly improved disease-free survival compared with surveillance [4]. Neoadjuvant cisplatin-based chemotherapy is increasingly considered for cisplatin-eligible patients with high-risk UTUC because renal function frequently declines after RNU, potentially limiting postoperative cisplatin eligibility. However, this approach is not supported by the same level of randomized, UTUC-specific evidence as adjuvant chemotherapy and may expose some patients to treatment-related toxicity or surgical delay without clear benefit. The iNDUCT trial is among the few prospective studies specifically evaluating neoadjuvant chemoimmunotherapy in localized UTUC. In this phase II study, neoadjuvant durvalumab combined with platinum-based chemotherapy demonstrated a pathologic complete response rate of approximately 19–21% and pathologic downstaging (